laninamivir increased ds market cap by ~1.8bn

I thought it would be interesting to see how the Laninamivir trial results has impacted the stock price of Daiichi Sankyo.

Interestingly, since the announcement the market cap has risen by around AUD1.8bn, a huge number! So who's correct? Aussie investors which priced in a LOWER share price since the release (total market cam ~360m) or Japanese investors pricing in an extra $1.8bn cap into Daiichi Sankyo?

http://advance.quote.nomura.co.jp/meigara/nomura2/quote.cgi?F=english/edchart&QCODE=4568&MKTN=T

This rise has been attributed to Laninamivir:

"Pharma stock Daiichi Sankyo Co. extended its winning streak to seven days Tuesday, buoyed by hopes for the drugmaker's new anti-influenza agent CS-8958, or laninamivir. On Monday afternoon, the drugmaker said that clinical trials have shown the new treatment to be more effective than Tamiflu, a popular product currently in the market, when administered to children aged nine and under."

http://www.ibtimes.com/articles/20090810/asian-markets-mostly-trading-flat-amid-cautious-mood.htm

I haven't checked the numbers, just looked at the chart and assumed 709m shares, exchange rate of 78... i don't have daily prices for DS unfortunately. Perhaps someone can reply with the correct figure if they have some time.